Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

Abstract: An exosome-based skincare product containing exosomes excreted by lab cultured human umbilical mesenchymal stem cells within a solvent. Most frequently the solvent is a mixture of water and glycerin. Optional ingredients such as skin-conditioning agents, antioxidants, surfactants, buffering agents, viscosity decreasing agents, viscosity increasing agents, peptides, binders, and/or humectants may be included.

Abstract: A saline nasal cleansing solution comprising: a water component; a humectant component; a salt component; a cleansing component; a surfactant component; a gelling component; a preservative component; an antioxidant component; and one or more natural extracts; wherein the cleansing component is ppg-26-butanol polyether-26; wherein the humectant component is sorbitol; wherein the salt component is sodium chloride; wherein the surfactant component is PEG-40 hydrogenated castor oil.

Abstract: The subject matter of the invention is a carrier loaded with bioactive substances, wherein the carrier is carbonate substituted hydroxyapatite and the bioactive substances are an ion and a plant extract, wherein the ion is selected from the group consisting of Cu, Zn and a combination thereof, and wherein the plant extract consists of mint extract, rosemary extract, Ocimum basilicum extract, lemon extract, garlic extract, clove extract, thyme extract and cinnamon extract.

Abstract: Disclosed herein are hair care compositions and methods of using same. The compositions may be substantially anhydrous, and optically clear. The hair care compositions, when mixed with water, create an exothermic reaction, for example, when mixed with hair that has been pre-wetted. The mixture with water further causes the composition to become opaque, much like a traditional conditioning agent. The compositions may be left on the wetted hair and subjected to heat for enhanced treatment of the hair.

Abstract: A method for applying a cosmetic composition to skin is disclosed. The method can include applying a first composition to skin that includes at least about 50% by weight of a volatile hydrocarbon, a film former, a solvent comprising an ester group, and a combination of ultraviolet A (UVA) and ultraviolet B (UVB) sunscreen agents, wherein the UVA sunscreen agent comprises 4-tert-butyl-4?-methoxydibenzoylmethane, wherein the first composition has an SPF of at least about 15 and a PFA of at least about 5, and wherein the first composition dries within two minutes after topical application to skin, and subsequently applying the cosmetic composition onto the first composition.

Abstract: The present technology generally relates to an encapsulation system for delivery of an active agent, the encapsulation system comprising a matrix of microcapsules, wherein a first portion of microcapsules in the matrix of microcapsules has an average diameter of from about 0.1 microns to about 10 microns; a second portion of the microcapsules has an average diameter of from about 10 microns to about 100 microns; and a third portion of the microcapsules has an average diameter of from about 100 microns to about 500 microns; and wherein the active agent is encapsulated in the microcapsules.

Abstract: Disclosed herein are a biodegradable polymer microparticle for a filler comprising a core and a shell, wherein the core contains secondary particles including aggregates of a plurality of primary particles, the shell has a raspberry shaped structure, an average particle diameter (D50) of the biodegradable polymer microparticle ranges from 20 to 200 ?m, a manufacturing method thereof, a freeze-dried body including the same, and filler injection including the same.

Abstract: The low aqueous solubility of roflumilast in parenteral preparations and topical emulsions, suspensions, gels or solutions can be improved by including a blend of water-miscible solvents in the pharmaceutical composition. The blend of water-miscible solvents can include diethylene glycol monoethyl ether (Tradename Transcutol®; abbreviated DEGEE) and water. The ratio of diethylene glycol monoethyl ether to water is from 1:10 to 20:1. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Abstract: In an embodiment, the present disclosure relates to a composition for treating or preventing a skin condition. In some embodiments, the composition includes zinc oxide with a concentration between about 5 and 30 wt/wt %, coconut oil with a concentration between about 0.1 and 5 wt/wt %, tea tree oil with a concentration between about 0.00025 and 0.1 wt/wt %, citronella oil with a concentration between about 0.00025 and 0.1 wt/wt %, and lemongrass oil with a concentration between about 0.01 and 1 wt/wt %. In a further embodiment, the present disclosure pertains to a composition for treating or preventing a skin condition including zinc oxide with a concentration of about 24 wt/wt %, coconut oil with a concentration of about 1 wt/wt %, tea tree oil with a concentration of about 0.001 wt/wt %, citronella oil with a concentration of about 0.001 wt/wt %, and lemongrass oil with a concentration of about 0.08 wt/wt %.

Abstract: A solid pharmaceutical composition is provided that includes a core, an inner coating, and an outer coating. The core includes tiopronin as an active agent. Further, the inner coating, which includes a cellulose-based polymer, surrounds the core, and the outer coating, which includes an enteric polymer, surrounds the inner coating. As a result of the specific components of the solid pharmaceutical composition, the solid pharmaceutical composition exhibits a fed state Cmax of tiopronin that is at least 70% of a 12-hour fasted state Cmax of tiopronin after oral administration of the solid pharmaceutical composition when administered as a 300 milligram dose. As such, it is possible for the solid pharmaceutical composition to be administered orally with or without food (e.g., in a fed or fasted state) while still achieving a desired maximum plasma concentration of the tiopronin in a delayed release formulation.

Abstract: The present invention provides a method for preparing an high internal phase of pumpkin seed protein nanoparticles, including dissolving pumpkin seed protein powder in water and adjusting pH to approximately 8 to 11 to obtain a pumpkin seed protein solution; adding the pumpkin seed protein solution through a peristaltic pump into an ethanol solution with stirring for 4 hours to obtain a first solution; performing a centrifugation to the first solution and collecting precipitates; diluting the precipitates with water and performing a freeze-drying to obtain the pumpkin seed protein nanoparticles. The present invention first uses an anti-solvent method to prepare pumpkin seed protein nanoparticles, which have excellent emulsifying properties and can stabilize the high internal phase emulsion. In addition, the resulting pumpkin seed protein nanoparticles can stabilize the high internal phase emulsion independently without compounding with other substances.

Abstract: The invention discloses an eyelash liquid eyeliner, wherein the raw materials comprise the following components in parts by weight: 50-60 parts of ethyl hexyl acrylate copolymer, 30-40 natural beeswax, 10-12 carnauba wax, 8-12 polyvinylpyrrolidone, 5-7 shellac, 1-3 black talc powder, 20-30 polyvinyl alcohol, 20-30 of silicone resins, 10-12 of codariocalyx motorius saponin extract, 5-7 dual-directional regulation growth promotion factors, 1-3 antifreeze, 1-3 coloring agent, 1-3 preservative, and 5-7 antioxidant. Components in the liquid eyeliner are replaced with natural substances of the natural beeswax, the carnauba wax, the shellac and the like, and the eyelash liquid eyeliner is safe to skin. Besides, organic silicone resins are added, so that the condition that the eyelash liquid eyeliner is broken up when being in contact with water can be effectively avoided, the organic silicone resin can effectively block ultraviolet rays and prevent the ultraviolet rays from destroying roots of eyelashes.

Abstract: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least water, at least alkylcellulose, at least a first nonvolatile oil chosen from silicone oils and/or fluoro oils, and at least a second hydrocarbon-based nonvolatile oil chosen from C10-C26 alcohols, preferably monoalcohols; monoesters, dieters or triesters of a C2-C8 monocarboxylic or polycarboxylic acid and of a C2-C8 alcohol, which are optionally hydroxylated; and polyesters of a C2-C8 polyol and of one or more C2-C8 carboxylic acids.

Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated oxidized regenerated cellulose (ORC) fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent; spraying the suspension through a nozzle onto a substrate, allowing the non-aqueous solvent to evaporate; separating from the substrate and sieving the composition.

Abstract: The present disclosure relates to an additive for soil conditioning and an agricultural composition comprising additive and plant growth regulator. The additive comprises a mixture of esters of fatty acids and an emulsifying agent. The additive of the present disclosure can be used in the conditioning of the soil which results in improvement in plant growth. The agricultural composition of the present disclosure can be used for improving soil condition and promoting plant growth.

Abstract: A treatment of human hair by means of solutions of Glyoxylic acid that, when used in combination with mechanical straightening by means of hair-straightening irons set at a temperature of approximately 200° C.+/?30° C., allow for the semi-permanent changing of the shape of hair from curly and/or frizzy to straight for at least six consecutive washings with water and shampoo.

Abstract: The present invention relates to a solid oral pharmaceutical dosage form suitable for making a suspension comprising acid labile benzimidazole compounds and process for preparing the same. The prior art discloses various technical challenges associated with the granules for reconstitution into suspension like agglomeration of particles, viscosity and gelling time. The solid oral pharmaceutical dosage form of the present invention forms a homogeneous suspension upon admixing with an aqueous medium and exhibits desired technical attributes like viscosity, drug release, gelling time, dissolution and reduced adherence to nasogastric and gastric tubes.

Abstract: Disclosed is an oil-in-water anionic emulsion for eyelashes, and methods for its use, comprising a continuous phase comprising 35 to 55% by weight of water based on the total weight of the emulsion, a discontinuous phase comprising 15 to 25% by weight of a combination of waxes, wherein the combination of waxes comprises paraffin wax, carnauba wax, beeswax, and candelilla wax based on the total weight of the emulsion, and 5 to 15% by weight of the emulsion of an anionic surfactant system comprising stearic acid, palmitic acid, myristic acid, polyethylene glycol-40 (PEG-40) stearate, and stearyl stearate, wherein the oil-in-water anionic emulsion is capable of thickening the appearance of eyelashes.

Abstract: The method of producing eggshell-derived nanoparticles may include steps of adding eggshell powder to methanol to form a solution; adding the solution dropwise to boiling water under ultrasonic conditions; incubating the resulting solution under continuous stirring at 200-800 rpm; and drying the resulting solution to obtain the eggshell-derived nanoparticles. The method produces nanoparticles of between 5 and 100 nm. Cytotoxicity testing shows that the nanoparticles exhibit anticancer activity against human breast cancer and lung cancer cell lines.